Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ELIAS HENRY SARKIS

Allopathic & Osteopathic Physicians Psychiatry & Neurology Child & Adolescent Psychiatry

NPI
1285749283
CMS profile
239756
Location
GAINESVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$16,210.05

84 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ELIAS HENRY SARKIS

NPI 1285749283 · CMS profile ID 239756

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Child & Adolescent Psychiatry

GAINESVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1285749283?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ELIAS HENRY SARKIS, NPI 1285749283, CMS profile ID 239756. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1285749283?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ELIAS HENRY SARKIS, NPI 1285749283, CMS profile ID 239756. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1285749283?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ELIAS HENRY SARKIS, NPI 1285749283, CMS profile ID 239756, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1285749283?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

84 matching records · $16,210.05 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 84 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–84 of 84.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Allergan, Inc. $6.4503/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723490203 CMS
Bausch Health US, LLC $13.9803/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737437283 CMS
Janssen Pharmaceuticals, Inc $14.9103/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719127199 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.2103/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747294557 CMS
Eisai Inc. $151.5303/01/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751338739 CMS
Eisai Inc. $826.4003/01/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751338741 CMS
Eisai Inc. $25.0003/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751338743 CMS
Eisai Inc. $50.0003/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751338745 CMS
Eisai Inc. $50.0003/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751338747 CMS
Eisai Inc. $130.3803/01/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751338749 CMS
Eisai Inc. $273.9803/01/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751338751 CMS
Eisai Inc. $27.0003/01/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751338753 CMS
Eisai Inc. $4,650.0003/01/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751338755 CMS
Eisai Inc. $25.0003/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751346241 CMS
Eisai Inc. $11.5003/01/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751346513 CMS
Neos Therapeutics, LP $13.7802/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753021225 CMS
Janssen Pharmaceuticals, Inc $10.9202/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719127201 CMS
Allergan, Inc. $8.8002/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723490201 CMS
Neos Therapeutics, LP $14.3702/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753021941 CMS
Teva Pharmaceuticals USA, Inc. $102.4302/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749518335 CMS
Otsuka America Pharmaceutical, Inc. $12.2102/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748786605 CMS
Janssen Pharmaceuticals, Inc $11.7402/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719127203 CMS
Allergan, Inc. $14.2602/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723490197 CMS
Allergan, Inc. $1,760.0002/04/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723490199 CMS
Allergan, Inc. $8.7901/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723490195 CMS
Ironshore Pharmaceuticals Inc. $16.4501/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737028769 CMS
Allergan, Inc. $2.4901/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723490193 CMS
Teva Pharmaceuticals USA, Inc. $14.2201/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749491533 CMS
Teva Pharmaceuticals USA, Inc. $9.6301/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749510271 CMS
Janssen Pharmaceuticals, Inc $22.5701/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719127197 CMS
Allergan, Inc. $6.9101/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723490191 CMS
Neos Therapeutics, LP $14.9101/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753022619 CMS
Allergan, Inc. $4.4501/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723490189 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.7001/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747294555 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $42,015.40 194
PY2020 $16,210.05 84
PY2021 $6,970.11 111
PY2022 $21,189.30 114
PY2023 $18,483.45 93
PY2024 $29,256.12 98
PY2025 $34,500.24 93

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $214,012.98 46
PY2024 Principal investigator $693,209.32 128
PY2023 Recipient $3,600.00 2
PY2023 Principal investigator $947,668.12 205
PY2022 Principal investigator $333,949.20 77
PY2021 Recipient $4,157.00 1
PY2021 Principal investigator $391,143.58 78
PY2020 Recipient $18,390.13 3
PY2020 Principal investigator $512,879.98 238
PY2019 Recipient $84,908.63 12
PY2019 Principal investigator $696,967.76 198

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

46 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $991.48 12/31/2025 Non-covered Recipient Entity
EHS MEDICAL PRACTICE
A 52-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Subjects with Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder No dispute reported 06/30/2026 1202532456
Principal investigator 2 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,000.00 11/03/2025 Non-covered Recipient Entity
SARKIS CLINICAL TRIALS
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242365073
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $400.00 10/13/2025 Non-covered Recipient Entity
EHS MEDICAL PRACTICE PA
ITI-007-601 No dispute reported 06/30/2026 1242363743
Principal investigator 1 ACADIA Pharmaceuticals Inc $18,691.55 09/15/2025 Non-covered Recipient Entity
ANZONI
ACP-103-070 No dispute reported 06/30/2026 1245936129
Principal investigator 1 ACADIA Pharmaceuticals Inc $3,478.65 09/15/2025 Non-covered Recipient Entity
ANZONI
ACP-103-070 No dispute reported 06/30/2026 1245936131
Principal investigator 1 ACADIA Pharmaceuticals Inc $5,623.70 09/10/2025 Non-covered Recipient Entity
ANZONI
ACP-103-070 No dispute reported 06/30/2026 1245936077
Principal investigator 1 ABBVIE INC. $3,600.00 08/26/2025 Non-covered Recipient Entity
THE EHS MEDICAL PRACTICE PA
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202505833
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $12,000.00 08/11/2025 Non-covered Recipient Entity
SARKIS CLINICAL TRIALS
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242356908
Principal investigator 1 ACADIA Pharmaceuticals Inc $4,392.05 08/04/2025 Non-covered Recipient Entity
ANZONI
ACP-103-070 No dispute reported 06/30/2026 1245935459
Principal investigator 1 ABBVIE INC. $6,000.00 07/22/2025 Non-covered Recipient Entity
THE EHS MEDICAL PRACTICE PA
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202499106
Principal investigator 1 ABBVIE INC. $3,500.00 07/18/2025 Non-covered Recipient Entity
THE EHS MEDICAL PRACTICE PA
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202498920
Principal investigator 1 ACADIA Pharmaceuticals Inc $30,821.29 07/07/2025 Non-covered Recipient Entity
ANZONI
ACP-103-069 No dispute reported 06/30/2026 1245934511
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $192.10 07/07/2025 Non-covered Recipient Entity
SARKIS CLINICAL TRIALS
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242352520
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,450.00 05/12/2025 Non-covered Recipient Entity
ANZONI
ACP-103-069 No dispute reported 06/30/2026 1245934217
Principal investigator 1 ABBVIE INC. $14,032.00 05/07/2025 Non-covered Recipient Entity
THE EHS MEDICAL PRACTICE PA
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202483651
Principal investigator 1 PFIZER INC. $1,112.99 04/24/2025 Non-covered Recipient Entity
The EHS Medical Practice Pa
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228763053
Principal investigator 1 PFIZER INC. $1,400.00 04/24/2025 Non-covered Recipient Entity
The EHS Medical Practice Pa
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1228776612
Principal investigator 1 ACADIA Pharmaceuticals Inc $21,812.76 04/15/2025 Non-covered Recipient Entity
ANZONI
ACP-103-070 No dispute reported 06/30/2026 1245934061
Principal investigator 1 ACADIA Pharmaceuticals Inc $973.05 04/15/2025 Non-covered Recipient Entity
ANZONI
ACP-103-070 No dispute reported 06/30/2026 1245934063
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,800.00 04/10/2025 Non-covered Recipient Entity
ANZONI
ACP-103-069 No dispute reported 06/30/2026 1245934047
Principal investigator 1 PFIZER INC. $1,000.00 04/04/2025 Non-covered Recipient Entity
The EHS Medical Practice Pa
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228778660
Principal investigator 1 ABBVIE INC. $24,885.00 04/03/2025 Non-covered Recipient Entity
THE EHS MEDICAL PRACTICE PA
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202473807
Principal investigator 1 PFIZER INC. $138.35 03/27/2025 Non-covered Recipient Entity
The EHS Medical Practice Pa
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1228765706
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $9,500.00 03/19/2025 Non-covered Recipient Entity
EHS MEDICAL PRACTICE PA
ITI-007-601 No dispute reported 06/30/2026 1242338313
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,800.00 03/19/2025 Non-covered Recipient Entity
EHS MEDICAL PRACTICE PA
ITI-007-601 No dispute reported 06/30/2026 1242338315
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $650.00 03/19/2025 Non-covered Recipient Entity
EHS MEDICAL PRACTICE PA
ITI-007-601 No dispute reported 06/30/2026 1242338337
Principal investigator 1 PFIZER INC. $733.55 03/13/2025 Non-covered Recipient Entity
The EHS Medical Practice Pa
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228767161
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,000.00 03/01/2025 Non-covered Recipient Entity
EHS MEDICAL PRACTICE PA DBA SARKIS CLINICAL TRIALS
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242333256
Principal investigator 1 PFIZER INC. $1,200.00 02/27/2025 Non-covered Recipient Entity
The EHS Medical Practice Pa
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228767290
Principal investigator 1 PFIZER INC. $1,400.00 02/27/2025 Non-covered Recipient Entity
The EHS Medical Practice Pa
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228768075
Principal investigator 1 PFIZER INC. $2,500.00 02/27/2025 Non-covered Recipient Entity
The EHS Medical Practice Pa
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228768083
Principal investigator 1 PFIZER INC. $1,800.00 02/27/2025 Non-covered Recipient Entity
The EHS Medical Practice Pa
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228768463
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,466.10 02/04/2025 Non-covered Recipient Entity
ANZONI
ACP-103-069 No dispute reported 06/30/2026 1245933454
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 02/01/2025 Non-covered Recipient Entity
Sarkis Clinical Trials
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646965
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 02/01/2025 Non-covered Recipient Entity
Sarkis Clinical Trials
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646967
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 02/01/2025 Non-covered Recipient Entity
Sarkis Clinical Trials
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646969
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,201.00 01/28/2025 Non-covered Recipient Entity
EHS Medical Practice Sarkis Clinical Trials
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220799509
Principal investigator 1 ACADIA Pharmaceuticals Inc $5,450.00 01/21/2025 Non-covered Recipient Entity
ANZONI
ACP-103-069 No dispute reported 06/30/2026 1245933381
Principal investigator 1 ACADIA Pharmaceuticals Inc $264.60 01/13/2025 Non-covered Recipient Entity
ANZONI
ACP-103-070 No dispute reported 06/30/2026 1245933215
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,395.98 01/06/2025 Non-covered Recipient Entity
ANZONI
ACP-103-070 No dispute reported 06/30/2026 1245933121
Principal investigator 1 PFIZER INC. $4,000.00 01/03/2025 Non-covered Recipient Entity
The EHS Medical Practice Pa
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228767327
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 01/01/2025 Non-covered Recipient Entity
Sarkis Clinical Trials
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646957
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 01/01/2025 Non-covered Recipient Entity
Sarkis Clinical Trials
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646959
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 01/01/2025 Non-covered Recipient Entity
Sarkis Clinical Trials
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646961
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 01/01/2025 Non-covered Recipient Entity
Sarkis Clinical Trials
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646963
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 01/01/2025 Non-covered Recipient Entity
Sarkis Clinical Trials
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646971